Among the cephalosporins available orally, cephalexin and cephradine have been shown to produce adequate serum levels and are used in the treatment of a variety of infections (3, 6, 8, 11, 14, 17) . Cephaloglycin, on the other hand, is poorly absorbed from the gastrointestinal tract (12, 13) . Recently, cefatrizine {7-[D-a-amino-a-(4-hydroxyphenyl)acetamido] -3-(1H-1,2,3,-triazol-5-ylthio methyl)-3-cephem-4-carboxylic acid}, at present an investigational drug (BL-S640), has been shown to be well absorbed in animals after oral and parenteral administration (10) .
The present study was undertaken to evaluate the in vitro activity of cefatrizine and its efficacy and safety in the treatment of infections due to susceptible organisms.
MATERIALS AND METHODS
Laboratory studies. The in vitro susceptibility of 256 recent clinical isolates to cefatrizine, cephalexin, cephalothin, cefazolin, and cephapirin was determined by the agar dilution method (2), using Mueller-Hinton agar (BBL), except in the case of Haemophilus influenzae, where GC medium base (BBL) supplemented with 1% hemoglobin (BBL) and 1% IsoVilateX (BBL) was used. Inoculation of the plates was performed by use of the Steers replicator (15) . Approximately 105 organisms were delivered to each plate for each representative organism. The minimal inhibitory concentration (MIC) was defined as the lowest concentration of antibiotic that inhibited growth after 18 h of incubation (24 h for H. influenzae) at 37 C. The susceptibility of the following bacteria was determined: 25 strains each of Escherichia coli and penicillinase-producing Staphylococcus aureus, 24 strains each ofProteus mirabilis, Streptococcus pneumoniae, and Streptococcus faecalis, 23 strains of group A streptococcus, 22 strains ofH. influenzae, 20 strains each ofKlebsiella sp. and penicillinase-negative S. aureus, 17 strains of Enterobacter sp., and 16 strains each of alphastreptococcus and indole-positive Proteus.
Disk susceptibility testing was done according to the standardized disk technique described by the Food and Drug Administration (4, 5) , with 3O-,g disks of cefatrizine obtained from Bristol Laboratories, Syracuse, N. Y. The zone diameter was then plotted against the MIC values and a regression curve was calculated by the method of least squares.
Serum levels from 19 patients were determined by disk plate assay (7), using Sarcina lutea ATCC 9341 as the test organism; when possible, assays were done at 1, 2, 3, and 6 h after the oral ingestion of multiple 6-hourly doses of 500 mg of cefatrizine, without regard to meals. The patients were receiving the drug for 2 to 4 days when the serum levels were obtained.
Clinical studies. The drug was administered orally to 33 patients with urinary tract infection, bacterial pneumonia, and skin and soft tissue infection due to susceptible organisms. Twenty-three patients were given 2 g/day and ten were given 1 g/day in four equal doses. Duration of treatment ranged from 5 to 20 days.
Appropriate bacterial cultures as well as hepatic (serum glutamic oxalacetic transaminase, bilirubin, alkaline phosphatase), renal (urinalysis, serum creatinine, blood urea nitrogen), and hematological (complete blood count) studies were done before, during, and after treatment. All patients were followed for 6 weeks after treatment was completed.
RESULTS
Antimicrobial activity. Comparison of the in vitro activity of cefatrizine with that of cephalexin, cephalothin, cefazolin, and cephapirin is shown in Fig. 1 through 10 . Against most of the gram-posi'tive organisms tested, cefatrizine was considerably more active than cephalexin, but less active than cephalothin, cefazolin, and cephapirin. Ninety-five percent of the strains of group A beta-hemolytic streptococcus were inhibited by less than 0.025 ,ug of cephapirin per ml and by 0.2 ,.ug of cefatrizine, cefazolin, and cephalothin per ml. Cephalexin inhibited 90% of the strains of group A streptococcus at a concentration of 1.6 ug/ml (Fig. 1 ). All strains of S. pneumoniae were inhibited by 0.4 ,ug of cefazolin, cephapirin, and cephalothin per ml and by 0.8 ,ug of cefatrizine per ml; in comparison, 6 .4 ,ug of cephalexin per ml was needed to inhibit all strains of S. pneumoniae (Fig. 2) .
One hundred percent of the strains of alphastreptococcus were inhibited by 0.8 ,ug of cefazolin and cephapirin per ml, by 1.6 ug of cephalothin and cefatrizine per ml, and by 25.6 ,ug of cephalexin per ml; however, 95% of the strains of alpha-streptococcus were inhibited by only 6.4 ,ug of cephalexin per ml (Fig. 3 ). All strains of S. aureus (penicillinase positive and negative) were inhibited by 1.6 ,ug of cefatrizine and 6.4 ug of cephalexin per ml (Fig. 4 and 5) . The parenteral cephalosporins were more active, especially cephalothin and cephapirin, which inhibited all strains of penicillinase-producing S. aureus at a concentration of 0.4 ug/ml (Fig. 4) . ANTIMICROB. AGENTS CHEMOTHER.
All strains of S. faecalis were resistant to the five cephalosporins tested.
Cefatrizine was the most active of the cephalosporins against most of the gram-negative organisms tested. Eighty percent of the E. coli strains were inhibited by 1.6 Ag of cefatrizine and cefazolin per ml. At the same concentration, cephalexin, cephalothin, and cephapirin inhibited less than 10% of the E. coli strains (Fig. 6 ). All strains of Klebsiella sp. were inhibited by 3.2 ug of cefatrizine and 6.4 ,ug of cefazolin per ml. Cephalothin, cephapirin, and cephalexin required a concentration of 12.8 ug/ ml to inhibit all strains of Klebsiella sp. (Fig.  7) . Only 35% of the strains of Enterobacter sp. were inhibited by 6.4 ug of cefatrizine per ml; less than 10% of the strains of Enterobacter sp.
were inhibited by 25.6 ,g or less of all the other cephalosporins per ml ( Serum concentrations. A mean peak serum level of 6.2 ,ug/ml was obtained 2 h after the previous dose following multiple 6-hourly doses of 500 mg of cefatrizine. After 6 hours the mean serum level was 1.6 ;g/ml. Compared with our previous studies with cephalexin (1) , it can be seen that the levels of cefatrizine were lower than those of cephalexin at 1 and 2 h but higher after 6 h (Table 1) ; these levels are, however, not entirely comparable since in the case of cephalexin they were obtained after a single dose, whereas those for cefatrizine were obtained after multiple doses.
Clinical results. A total of 33 patients were treated with cefatrizine; in 15 of these patients no pathogenic organism was isolated, but therapy was continued in 11 of them because clinical and laboratory evidence suggested a bacterial infection. These patients, however, were not included in the evaluation of the efficacy of the drug. Ofthe 18 patients in whom a bacterial pathogen was isolated, six had an acute urinary tract infection, seven had soft tissue infection, four had pneumonia, and one had bacterial conjunctivitis ( infections and the other was reinfected after a cystoscopic examination. These three patients were considered cured of their original infection. Two patients remained asymptomatic and with negative urine cultures for the 6 weeks post-treatment. Relapse with the original organism 3 days after discontinuation of therapy was encountered in one patient who had a right kidney stone and chronic pyelonephritis.
Four patients with pneumococcal pneumonia were treated with 2 g of cefatrizine daily for 7 days. All of them responded promptly and were afebrile within 24 to 48 h. Follow-up chest X rays showed complete clearing of the infiltrates in all of the patients.
Of the seven patients with soft tissue infections, four had subcutaneous abscesses and three had cellulitis. All of them were treated activity. It has been shown to be effective in the treatment of experimental infections of mice both orally and parenterally (10) . Earlier reports revealed that cefatrizine was more active in vitro than cephalexin, cephalothin, cephaloridine, and cefazolin against most gram-negative and some gram-positive organisms (9) . Studies done on mice showed that the therapeutic efficacy of cefatrizine compared with other cephalosporins was greater than predicted considering its comparative in vitro activity, and this was thought to be related to the longer half-life of cefatrizine in blood (10) . Our in vitro studies revealed that cefatrizine was more active than cephalexin for all grampositive and -negative organisms tested. It was also more active than cephalothin, cefazolin, and cephapirin against most of the gram-negative bacteria, but less active against the grampositive bacteria. The in vitro activity of cephradine was not tested since it has been shown to be almost identical to that of cephalexin (14) . The MICs of cefatrizine obtained in this study are comparable to those formerly reported (9) . Previous studies (9, 16) have revealed that 36.8% of indole-positive Proteus were inhibited by 8 ,ug or less and 50% of S. faecalis were inhibited by 16 Mg or less of cefatrizine per ml. In our study, however, both organisms were uniformly resistant. Only 35% of strains ofEnterobacter sp. were inhibited by 6.25 ,ug or less of cefatrizine per ml. However, this organism was more susceptible to cefatrizine than to the rest of the cephalosporins.
The peak serum levels obtained after oral ingestion of cefatrizine were lower than those of cephalexin, but they also declined at a slower rate. This phenomenon has also been observed in mice (10) . The serum levels necessary for inhibition of most susceptible organisms were well within the achievable range for cefatri- In conclusion, cefatrizine is a wide-spectrum cephalosporin, shown to be well tolerated and effective against infections caused by susceptible organisms when administered orally.
